BeyondDX announced on the 7th that it has hired Lee Kwang-hyeok, former head of SK Biopharm China, as its Chief Business Development Officer (CBO). Through this appointment, BeyondDX plans to accelerate its global business expansion, including the Chinese market.
CBO Lee Gwang-hyeok has participated in the research and development of new drugs for the nervous system since joining SK Energy Yukong, and is a global business expert who has been in charge of the clinical strategy and approval process for the CNS (central nervous system) treatment drug 'Cenobamate' in China since the early days of the establishment of SK Biopharm's Chinese subsidiary. He has overall business operation capabilities such as establishing Chinese market entry strategies, responding to local regulations, and building partnerships.
BeyondDX is currently developing a liquid biopsy-based early lung cancer screening test, 'ForeCheck LC', and an AI-based multi-biomarker diagnostic platform, and aims for objective diagnosis of major mental illnesses (depression, panic disorder, bipolar disorder, etc.). 'ForeCheck LC' has proven its technological prowess through numerous clinical trials, showing high sensitivity even in stage 1-2 early lung cancer.
A BeyondDX official said, “The addition of CBO Lee Kwang-hyeok will be a significant turning point in our entry into the Asian market, including China,” and added, “We expect synergy in global clinical and licensing strategies, establishing local partnerships, and technology transfer.”
CBO Lee Kwang-hyeok said, “I evaluate BeyondDX as a company that demonstrates the possibility of realizing precision medicine in the fields of cancer and mental illness that require early diagnosis,” and added, “I will accelerate my entry into the Chinese and global markets and strategic partnerships based on my experience.”
You must be logged in to post a comment.